Browse by category

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Innovent Biologics’ New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and...

The FDA has cleared Veru’s Investigational New Drug (IND) application for its Phase 2b clinical study to evaluate enobosarm, an oral...

Bariatric surgery is more effective in controlling hypertension rates in people with obesity and uncontrolled high blood pressure...

The ‘Obesity, the Big Truth’ initiative provides a framework for physicians and surgeons to work alongside patient advocates to host...

Tirzepatide significantly lowered the systolic blood for nearly 500 adults with obesity who took the medication for about eight months,...

Disrupted function of “cleaning cells” in the body may help to explain why some people with obesity develop type 2 diabetes, while others...

The FDA has cleared NeuroBo Pharmaceuticals’ Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM)...

It was another busy month reporting the latest bariatric and metabolic, and obesity-related disease news. We hope we have brought you the...

NLRP3 activation is associated with a pathologic inflammatory response in children with obesity and with insulin resistance increasing...